Current and historical daily PE Ratio for Acorda Therapeutics Inc (
STU:CDG
) from 2014 to Jun 21 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Acorda Therapeutics stock (STU:CDG) PE ratio as of Jun 21 2024 is 0.
More Details
Acorda Therapeutics Inc (STU:CDG) PE Ratio (TTM) Chart
Acorda Therapeutics Inc (STU:CDG) PE Ratio (TTM) Historical Data
View and export this data going back to 2014. Start your Free Trial
Total 1300
- 1
- 2
- 3
- 4
- 5
- 6
- 15
Acorda Therapeutics PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-21 | At Loss | 2024-04-19 | At Loss |
2024-06-20 | At Loss | 2024-04-18 | At Loss |
2024-06-19 | At Loss | 2024-04-17 | At Loss |
2024-06-18 | At Loss | 2024-04-16 | At Loss |
2024-06-17 | At Loss | 2024-04-15 | At Loss |
2024-06-14 | At Loss | 2024-04-12 | At Loss |
2024-06-13 | At Loss | 2024-04-11 | At Loss |
2024-06-12 | At Loss | 2024-04-10 | At Loss |
2024-06-11 | At Loss | 2024-04-09 | At Loss |
2024-06-10 | At Loss | 2024-04-08 | At Loss |
2024-06-07 | At Loss | 2024-04-05 | At Loss |
2024-06-06 | At Loss | 2024-04-04 | At Loss |
2024-06-05 | At Loss | 2024-04-03 | At Loss |
2024-06-04 | At Loss | 2024-04-02 | At Loss |
2024-06-03 | At Loss | 2024-04-01 | At Loss |
2024-05-31 | At Loss | 2024-03-29 | At Loss |
2024-05-30 | At Loss | 2024-03-28 | At Loss |
2024-05-29 | At Loss | 2024-03-27 | At Loss |
2024-05-28 | At Loss | 2024-03-26 | At Loss |
2024-05-27 | At Loss | 2024-03-25 | At Loss |
2024-05-24 | At Loss | 2024-03-22 | At Loss |
2024-05-23 | At Loss | 2024-03-21 | At Loss |
2024-05-22 | At Loss | 2024-03-20 | At Loss |
2024-05-21 | At Loss | 2024-03-19 | At Loss |
2024-05-20 | At Loss | 2024-03-18 | At Loss |
2024-05-17 | At Loss | 2024-03-15 | At Loss |
2024-05-16 | At Loss | 2024-03-14 | At Loss |
2024-05-15 | At Loss | 2024-03-13 | At Loss |
2024-05-14 | At Loss | 2024-03-12 | At Loss |
2024-05-13 | At Loss | 2024-03-11 | At Loss |
2024-05-10 | At Loss | 2024-03-08 | At Loss |
2024-05-09 | At Loss | 2024-03-07 | At Loss |
2024-05-08 | At Loss | 2024-03-06 | At Loss |
2024-05-07 | At Loss | 2024-03-05 | At Loss |
2024-05-06 | At Loss | 2024-03-04 | At Loss |
2024-05-03 | At Loss | 2024-03-01 | At Loss |
2024-05-02 | At Loss | 2024-02-29 | At Loss |
2024-05-01 | At Loss | 2024-02-28 | At Loss |
2024-04-30 | At Loss | 2024-02-27 | At Loss |
2024-04-29 | At Loss | 2024-02-26 | At Loss |
2024-04-26 | At Loss | 2024-02-23 | At Loss |
2024-04-25 | At Loss | 2024-02-22 | At Loss |
2024-04-24 | At Loss | 2024-02-21 | At Loss |
2024-04-23 | At Loss | 2024-02-20 | At Loss |
2024-04-22 | At Loss | 2024-02-19 | At Loss |
Acorda Therapeutics Inc (STU:CDG) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
![Acorda Therapeutics Inc Acorda Therapeutics Inc logo](https://static.gurufocus.com/logos/0C00000HBB.png?14)
Acorda Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US00484M1062
Share Class Description:
STU:CDG: Ordinary SharesDescription
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis. The company's Net product revenue is derived from the sales of Ampyra and Inbrija.